Prophylactic therapy in haemophilia.
Forskningsoutput: Tidskriftsbidrag › Översiktsartikel
Standard
Prophylactic therapy in haemophilia. / Ljung, Rolf.
I: Blood Reviews, Vol. 23, Nr. 6, 2009, s. 267-274.Forskningsoutput: Tidskriftsbidrag › Översiktsartikel
Harvard
APA
CBE
MLA
Vancouver
Author
RIS
TY - JOUR
T1 - Prophylactic therapy in haemophilia.
AU - Ljung, Rolf
PY - 2009
Y1 - 2009
N2 - Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is beneficial but less cost-effective. This review covers proof of concept of primary prophylaxis in children and secondary prophylaxis in adults, comparisons between prophylaxis and on demand treatment as well as outcome measurers, health economics and future trends of prophylactic treatment of hemophilia.
AB - Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is beneficial but less cost-effective. This review covers proof of concept of primary prophylaxis in children and secondary prophylaxis in adults, comparisons between prophylaxis and on demand treatment as well as outcome measurers, health economics and future trends of prophylactic treatment of hemophilia.
U2 - 10.1016/j.blre.2009.08.001
DO - 10.1016/j.blre.2009.08.001
M3 - Review article
VL - 23
SP - 267
EP - 274
JO - Blood Reviews
JF - Blood Reviews
SN - 1532-1681
IS - 6
ER -